Non-transfusion-dependent thalassemia and thalassemia intermedia: Epidemiology, complications, and management

Current Medical Research and Opinion

Volumn 32, Issue 1, 2016, Pages 191-204

  Vichinsky, Elliott ^a,b  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Iron chelation therapy; Iron overload; Nontransfusion dependent thalassemia; Thalassemia intermedia

Indexed keywords

DEFERASIROX; ERYTHROPOIETIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEPCIDIN; HYDROXYUREA; IRON CHELATING AGENT;

ALPHA THALASSEMIA; ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE DISEASE; BRAIN ATROPHY; BRAIN INFARCTION; COGNITIVE DEFECT; ENDOCRINE DISEASE; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; GENETIC SCREENING; GLOBIN GENE; GROWTH DISORDER; GROWTH RETARDATION; HEART FAILURE; HEMOGLOBIN E-BETA THALASSEMIA; HEMOGLOBIN H DISEASE; HEMOLYSIS; HEMOSIDEROSIS; HUMAN; HYPERCOAGULABILITY; HYPERSPLENISM; INTRAUTERINE GROWTH RETARDATION; IRON ABSORPTION; IRON OVERLOAD; JAUNDICE; LEG ULCER; LIVER DISEASE; MEDICAL HISTORY; NEUROLOGICAL COMPLICATION; NON TRANSFUSION DEPENDENT THALASSEMIA; OSTEOPOROSIS; PARAPLEGIA; PATHOGENESIS; PEER REVIEW; PREGNANCY COMPLICATION; PREMATURITY; PSEUDOTUMOR; PUBLIC HEALTH PROBLEM; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SCREENING; SKELETON MALFORMATION; SPINAL CORD COMPRESSION; SPLENECTOMY; SPLENOMEGALY; THALASSEMIA; THALASSEMIA INTERMEDIA; THROMBOEMBOLISM; THROMBOSIS; WHITE MATTER LESION; COMPLICATION;

BLOOD TRANSFUSION; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; QUALITY OF LIFE; THALASSEMIA;

EID: 84952873261     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1110128     Document Type: Review

References (76)

1. Weatherall DJ. The definition and epidemiology of non-Transfusion-dependent thalassemia. Blood Rev 2012; 26 (Suppl 1): S3-6
2. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-Transfusion-dependent thalassemias. Haematologica 2013; 98: 833-44
3. Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non-Transfusion-dependent thalassaemia. Vox Sang 2015; 108: 1-10
4. Harteveld CL, Higgs DR. Alpha-Thalassemia. Orphanet J Rare Dis 2010; 5: 13
5. Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med 2012; 2 (8
6. Borgna-Pignatti C, Marasella M, Zanforlin N. The natural history of thalassemia intermedia. Ann NY Acad Sci 2010; 1202: 214-20
7. Vichinsky E. Hemoglobin E syndromes. Hematology Am Soc Hematol Educ Program 2007;: 79-83
8. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010; 115: 4331-6
9. Cohen AR, Galanello R, Pennell DJ, et al. Thalassemia. Hematology Am Soc Hematol Educ Program 2004;: 14-34
10. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann NY Acad Sci 2005; 1054: 18-24
11. Pakbaz Z, Treadwell M, Yamashita R, et al. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann NY Acad Sci 2005; 1054: 457-61
12. Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80: 70-4
13. Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β thalassemia intermedia. Blood Cells Mol Dis 2013; 51: 35-8
14. Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8: 54-9
15. Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-Thalassemia intermedia: breaking the silence. Thromb Res 2012; 130: 695-702
16. Voskaridou E, Balassopoulou A, Boutou E, et al. Pregnancy in beta-Thalassemia intermedia: 20-year experience of a Greek thalassemia center. Eur J Haematol 2014; 93: 492-9
17. Lal A, Goldrich MJ, Haines DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011; 364: 710-18
18. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111: 467-73
19. Tantawy AA, Adly AA, Mahdy SA, Kamel GZ. Spinal cord compression and extramedullary hematopoiesis in young Egyptian beta-Thalassemia patients. Hemoglobin 2009; 33: 448-62
20. Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: four case reports. Hematology 2015; 20: 53-7
21. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007; 49: 329-32
22. Haines D, Martin M, Carson S, et al.; Thalassemia Clinical Research Network. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 2013; 160: 680-7
23. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br J Haematol 2010; 150: 486-9
24. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52: 486-90
25. Choy J, Foote D, Bojanowski J, et al. Outreach strategies for southeast Asian communities: experience, practice, and suggestions for approaching southeast Asian immigrant and refugee communities to provide thalassemia education and trait testing. J Pediatr Hematol Oncol 2000; 22: 588-92
26. Lorey F, Cunningham G, Vichinsky EP, et al. Universal newborn screening for Hb H disease in California. Genet Test 2001; 5: 93-100
27. Hoppe CC. Newborn screening for non-sickling hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2009;: 19-25
28. Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005; 116: e818-25
29. Vichinsky E, Neumayr L, Trimble S, et al.; CDC Thalassemia Investigators. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion 2014; 54: 972-81; quiz 971
30. Viprakasit V, Tyan P, Rodmai S, Taher AT. Identification and key management of non-Transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J Rare Dis 2014; 9: 131
31. Taher A, Vichinsky E, Musallam K, et al. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation, 2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK190453
32. Cui J, Azimi M, Baysdorfer C, et al. Application of multiplex ligation-dependent probe amplification to screen for β-globin cluster deletions: detection of two novel deletions in a multi ethnic population. Hemoglobin 2013; 37: 241-56
33. Haddad A, Tyan P, Radwan A, et al. Beta-Thalassemia intermedia: a birds eye view. Turk J Haematol 2014; 31: 5-16
34. Vogiatzi MG, Macklin EA, Fung EB, et al.; Thalassemia Clinical Research Network. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009; 24: 543-57
35. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115: 1886-92
36. Fung EB, Xu Y, Trachtenberg F, et al.; Thalassemia Clinical Research Network. Inadequate dietary intake in patients with thalassemia. J Acad Nutr Diet 2012; 112: 980-90
37. Fung EB, Kwiatkowski JL, Huang JN, et al. Zinc supplementation improves bone density in patients with thalassemia: a double blind, randomized, placebo-controlled trial. Am J Clin Nutr 2013; 98: 960-71
38. Fung EB, Vichinsky EP, Kwiatkowski JL, et al. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 2011; 48: 1305-12
39. Giusti A. Bisphosphonates in the management of thalassemia-Associated osteoporosis: a systematic review of randomised controlled trials. J Bone Miner Metab 2014; 32: 606-15
40. Vichinsky E, Levine L, Bhatia S, et al. Standards of Care Guidelines for Thalassemia, 2012. Oakland, CA: Childrens Hospital & Research Cancer Oakland. Available at: https://thalassemia.com/documents/SOCGuidelines2012.pdf [Last accessed 15 August 2014
41. Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000; 96: 3369-73
42. Haidar R, Mhaidli H, Musallam KM, Taher AT. The spine in β-Thalassemia syndromes. Spine (Phila Pa 1976) 2012; 37: 334-9
43. Esfandbod M, Malekpour M. Thalassemia and spinal cord compression in pregnancy. CMAJ 2010; 182: E798
44. Karimi M, Haghpanah S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with β thalassemia intermedia. Ann Hematol 2012; 91: 1833-8
45. Brousse V, Hertz-Pannier L, Consigny Y, et al. Does regular blood transfusion prevent progression of cerebrovascular lesions in children with sickle cell disease? Ann Hematol 2009; 88: 785-8
46. Riddington C, Wang W. Blood transfusion for preventing stroke in people with sickle cell disease. Cochrane Database Syst Rev 2002; 1: CD003146. Update in: Cochrane Database Syst Rev 2013;11:CD003146
47. Morris CR, Vichinsky EP. Pulmonary hypertension in thalassemia. Ann NY Acad Sci 2010; 1202: 205-13
48. Morris CR, Kim HY, Wood J, et al. Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. Haematologica 2013; 98: 1359-67
49. Derchi G, Balocco M, Bina P, et al. Efficacy and safety of sildenafil for the treatment of severe pulmonary hypertension in patients with hemoglobinopathies: results from a long-Term follow up. Haematologica 2014; 99: e17-8
50. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011; 96: 1605-12
51. Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann NY Acad Sci 2010; 1202: 231-6
52. Taher A, Ismaeel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96: 488-91
53. Danjou F, Cabantchik ZI, Origa R, et al A decisional algorithm to start iron chelation in patients with beta thalassemia. Haematologica 2014; 99: e38-40
54. Vichinsky EP. Emerging therapy in hemoglobinopathies: lessons from the past and optimism for the future. Hematol Oncol Clin North Am 2014; 28: xiii-xviii
55. Barton JC. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders. IDrugs 2007; 10: 270-81
56. Breda L, Rivella S. Modulators of erythropoiesis emerging therapies for hemoglobinopathies and disorders of red cell production. Hematol Oncol Clin North Am 2014; 28: 375-86
57. Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013; 123: 2337-43
58. Schmidt PJ, Fleming MD. Modulation of hepcidin as therapy for primary and secondary iron overload disorders preclinical models and approaches. Hematol Oncol Clin North Am 2014; 28: 387-401
59. Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E. Darbepoetin alfa for the treatment of anaemia in alpha- or beta- Thalassaemia intermedia syndromes. Br J Haematol 2011; 154: 281-4
60. Perrine SP, Pace BS, Faller DV. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Hematol Oncol Clin North Am 2014; 28: 233-48
61. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-76
62. Cappellini MD, Cohen A, Piga A, et al A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-Thalassemia. Blood 2006; 107: 3455-62
63. Ferriprox [prescribing information]. Rockville, MD: ApoPharma USA Inc., April 2012
64. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-Thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122: 305-10
65. Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 2006; 133: 198-205
66. Vichinsky E, Bernaudin F, Forni GL, et al. Long-Term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154: 387-97
67. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012; 120: 970-7
68. Exjade [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, October 2013
69. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-Thalassemia. Clin Ther 2007; 29: 909-17
70. Vichinsky E, Onyekwere O, Porter J, et al.; Deferasirox in Sickle Cell Investigators A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-8
71. Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with β-Thalassemia. Blood 2013; 121: 2199-212; quiz 2372
72. Attie KM, Allison MJ, McClure T, et al A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol 2014; 89: 766-70
73. Piga AG, Perrotta S, Melpignano A, et al. ACE-536 increases hemoglobin and decreases transfusion burden and serum ferritin in adults with beta-Thalassemia: preliminary results from a phase 2 study. Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. December 6-9, 2014; San Francisco, California. 2014; 124: 53
74. Rivella S. Ineffective erythropoiesis and thalassemias. Curr Opin Hematol 2009; 16: 187-94
75. Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-Transfusion-dependent thalassemia. Am J Hematol 2013; 88: 409-15
76. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-Transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013; 92: 1485-93